Immune Pharmaceuticals Inc  

(Public, NASDAQ:IMNP)   Watch this stock  
Find more results for IMNP
-0.09 (-2.95%)
Real-time:   12:48PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.95 - 3.07
52 week 2.14 - 12.80
Open 3.04
Vol / Avg. 84,942.00/914,574.00
Mkt cap 25.51M
P/E     -
Div/yield     -
EPS -14.56
Shares 8.67M
Beta 1.84
Inst. own 4%
Apr 18, 2017
Immune Pharmaceuticals Inc at CF&B Communication European SmallCap Event
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -154.92% -46.34%
Return on average equity -823.61% -196.18%
Employees 12 -
CDP Score - -


430 East 29Th Street, Suite 940
NEW YORK, NY 10016
United States - Map
+1-646-4409310 (Phone)
+1-917-3981915 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Immune Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of targeted therapeutics in the fields of immuno-inflammation and immuno-oncology. The Company's segment is acquiring, developing and commercializing prescription drug products. Its Immuno-inflammation product pipeline includes bertilimumab, a fully human antibody targeting eotaxin-1, a regulator of immuno-inflammation; a portfolio of immune oncology products, and NanoCyclo, a topical nanocapsule formulation of cyclosporine-A, for the treatment of atopic dermatitis and psoriasis. Its immuno-oncology pipeline includes Ceplene, a small molecule targeting the Histamine-2 Receptor to overcome immunosuppression in Acute Myeloid Leukemia and other malignancies. Azixa and crolibulin are vascular disrupting agents. NanomAbs is a technology platform that allows the targeted delivery of chemotherapeutics into cancer cells.

Officers and directors

Monica E. Luchi President, Executive Vice President - Global Drug Development, Chief Medical Officer
Bio & Compensation  - Reuters
John Militello CPA Principal Financial Officer, Chief Accounting Officer, Vice President - Finance, Controller
Age: 42
Bio & Compensation  - Reuters
Cameron Durrant M.D. Lead Independent Director
Age: 54
Bio & Compensation  - Reuters
Daniel G. Teper Pharm.D. Director
Age: 55
Bio & Compensation  - Reuters
Elliot M. Maza J.D., CPA Independent Director
Age: 61
Bio & Compensation  - Reuters
John A Neczesny Independent Director
Bio & Compensation  - Reuters
Jeffrey Paley M.D. Independent Director
Age: 47
Bio & Compensation  - Reuters